diminazene has been researched along with Uveitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lei, B; Li, Q; Qiu, Y; Shil, PK; Verma, A; Yang, H; Zhu, P | 1 |
| Chen, Z; Lei, B; Lei, C; Qiu, Y; Yang, H; Zheng, C; Zheng, S | 1 |
2 other study(ies) available for diminazene and Uveitis
| Article | Year |
|---|---|
Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.
Topics: Angiotensin-Converting Enzyme 2; Animals; Anterior Eye Segment; Diminazene; Disease Models, Animal; Enzyme Activation; Female; Follow-Up Studies; Intercalating Agents; Mice; Mice, Inbred BALB C; Ophthalmic Solutions; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Uveitis | 2014 |
Topical administration of diminazene aceturate decreases inflammation in endotoxin-induced uveitis.
Topics: Administration, Ophthalmic; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents; Aqueous Humor; Cyclooxygenase 2; Dexamethasone; Diminazene; Female; Gene Expression; Injections, Intraperitoneal; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Nitric Oxide Synthase Type II; Ophthalmic Solutions; p38 Mitogen-Activated Protein Kinases; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Uvea; Uveitis | 2015 |